ORIGINAL ARTICLE

Responses to the Dix-Hallpike test in primary care: A comparison between subjective and objective benign paroxysmal positional vertigo

José Luis Ballve Morenoa,*, Ricard Carrillo Muñozb, Yolanda Rando Matosc, Iván Villar Balboab, Oriol Cunillera Puértolasc, Jesús Almeda Ortegac

a Equip d’Atenció Primària Florida Nord, Institut Català de la Salut, Hospitalet de Llobregat, Barcelona, Spain
b Equip d’Atenció Primària Florida Sud, Institut Català de la Salut, Hospitalet de Llobregat, Barcelona, Spain
c Unitat de Suport a la Recerca Metropolitana Sud, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Spain

Received 25 June 2020; accepted 5 January 2021

KEYWORDS
Benign paroxysmal positional vertigo; Primary care; Pathologic nystagmus

Abstract Patients who experience both vertigo and nystagmus in the Dix-Hallpike test (DHT) are diagnosed with objective benign paroxysmal positional vertigo (BPPV). This test provokes only vertigo in between 11% and 48% of patients, who are diagnosed with subjective BPPV. Detection of nystagmus has important diagnostic and prognostic implications. To compare the characteristics of patients diagnosed with objective and subjective BPPV in primary care. Cross-sectional descriptive study. Two urban primary care centers. Adults (≥18 years) diagnosed with objective or subjective BPPV between November 2012 and January 2015. DHT results (vertigo or vertigo plus nystagmus; dependent variable: nystagmus as response to DHT), age, sex, time since onset, previous vertigo episodes, self-reported vertigo severity (Likert scale, 0–10), comorbidities (recent viral infection, traumatic brain injury, headache, anxiety/depression, hypertension, diabetes mellitus, dyslipidemia, cardiovascular disease, altered thyroid function, osteoporosis, cervical spondylosis, neck pain). In total, 134 patients (76.1% women) with a mean age of 52 years were included; 59.71% had subjective BPPV. Objective BPPV was significantly associated with hypertension, antihypertensive therapy, and cervical spondylosis in the bivariate analysis and with cervical spondylosis (OR = 3.94, p = 0.021) and antihypertensive therapy (OR = 3.02, p = 0.028) in the multivariate analysis. Patients with subjective BPPV were more likely to be taking benzodiazepines [OR 0.24, p = 0.023]. The prevalence of subjective BPPV was higher than expected. Cervical spondylosis and hypertensive therapy were associated with objective BPPV, while benzodiazepines were associated with subjective BPPV.

© 2021 The Authors. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author.
E-mail address: ballveji@gmail.com (J.L.B. Moreno).

https://doi.org/10.1016/j.aprim.2021.102023
0212-6567/© 2021 The Authors. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Vertigo is a common complaint that places a considerable burden on primary care services.\textsuperscript{1} Benign paroxysmal positional vertigo (BPPV) accounts for between 17% and 42% of all cases, with an annual incidence of between 10.7 and 140 cases per 100,000 inhabitants.\textsuperscript{2,3} BPPV is characterized by a short-lived rotating sensation induced by changes in head position. The posterior canal is the main canal affected (60% to 90% of cases).\textsuperscript{4} Posterior canal BPPV can be diagnosed in primary care with a targeted history, a basic physical examination, and administration of the Dix-Hallpike (DHT) test. This test is considered positive when it triggers both symptoms (vertigo) and nystagmus. Thedagnosis in this case is objective BPPV.\textsuperscript{5} The test may also be considered positive when it triggers vertigo only. In this case, the patient is diagnosed with subjective BPPV.\textsuperscript{6,7} Subjective BPPV is very common and accounts for between 11.5%\textsuperscript{8} and 48%\textsuperscript{9} of all cases of BPPV. One possible explanation for the absence of nystagmus is that the dislodged otolithic particles in the posterior semicircular canal may be sufficient to cause vertigo but not nystagmus.\textsuperscript{7} It is also possible that mild nystagmus may go unnoticed if specialized equipment, such as videonystagmography systems or Frenzel goggles, is not used.\textsuperscript{6} The likelihood of a false-negative result is therefore greater in primary care, where between 60% and 80% of patients with BPPV are seen.\textsuperscript{10} In a randomized clinical trial analyzing the effectiveness of the Epley maneuver in the treatment of posterior canal BPPV in primary care, our group found that this maneuver was only effective in patients who had both vertigo and nystagmus at baseline (objective BPPV).\textsuperscript{11} Detection of nystagmus therefore has important diagnostic and prognostic implications and studies are needed to investigate factors associated with this condition.\textsuperscript{12}

The aim of this study was to analyze factors associated with the presence or absence of nystagmus in the DHT in primary care patients with posterior canal BPPV.

Method

Study design

Descriptive, cross-sectional study based on the basal visit of a clinical trial with the objective to demonstrate the effectiveness of the Epley maneuver to treat PC-BPPV in primary care. ClinicalTrials.gov Identifier: NCT01969513.\textsuperscript{13}

Setting

Two primary care centers with 26 general practitioners serving an approximate population of 38,305 people in L'Hospitalet de Llobregat (Barcelona, Spain).

Inclusion criteria

Patients aged 18 years or older with posterior canal BPPV and a positive DHT for vertigo only or for vertigo plus nystagmus.
Patients who had neither vertigo nor nystagmus with DHT were excluded from the study.

Exclusion criteria

Suspected Menière’s disease, labyrinthitis, vestibular neuritis, pregnancy, breastfeeding, and contraindications for performance of the DHT or Epley maneuver or treatment with betahistine. Patients with findings suggestive of involvement of a semicircular canal other than the posterior canal or any other diagnosis, such as vertigo of central origin, were also excluded and referred to an ear, nose, and throat specialist. Nineteen of the patients were excluded following recruitment because they had findings consistent with vestibular migraine. Although this possibility was not contemplated in the initial protocol, vestibular migraine is very common and findings published after our study was designed have shown that this condition has overlapping symptoms with BPPV.

Participant selection

Consecutive patients with symptoms consistent with a diagnosis of posterior canal BPPV were recruited by GPs at the two participating primary care centers. The recruitment period was November 2012 to January 2015.

Procedures

The recruiting team took a full history from the patients, performed a full physical examination, and revised their electronic health records. The baseline DHT was considered positive if it triggered vertigo and nystagmus (objective BPPV) or vertigo only (subjective BPPV) when performed on either the right or left side.

The following variables were recorded for all patients:

- Dependent variables: presence or absence of nystagmus in the DHT.
- Independent variables: age; sex; time since onset of symptoms, self-reported severity of vertigo symptoms on a Likert scale of 0–10, where 0 corresponds to no symptoms and 10 to the worst imaginable symptoms; history of recent viral infection, traumatic brain injury, headache, anxiety/depression, hypertension, diabetes mellitus, dyslipidemia, cardiovascular disease, altered thyroid function, osteoporosis, cervical spondylosis, neck pain; pharmacological treatment of vertigo (betahistine as monotherapy or combined therapy or treatment with dimenhydrinate, sulpiride, or tietykerazine); other treatments (anti-depressants, benzodiazepines, and anti-hypertensives).

Analysis and statistical tests

The sample size was calculated based on outcomes not presented in this paper, as the original trial was designed to determine the effectiveness of the Epley maneuver in the treatment of posterior canal BPPV in primary care. There were 66 patients in the intervention group (treated with the Epley maneuver and betahistine) and 68 in the control group (treated with a sham maneuver and betahistine).

Results

Fig. 1 shows study flowchart.

We included 134 patients (76.1% women) with a median age of 52 years (interquartile range [IQR], 38.2–68.0 years). According to the baseline DHT, 59.7% of the patients had subjective BPPV and 40.3% had objective BPPV (Table 1).

Patients with objective BPPV were more likely to have a history of hypertension (p = 0.043) or to be on treatment with antihypertensives (p = 0.046). We also detected a tendency toward a history of cervical spondylosis (p = 0.059). No significant differences were found between the groups for any of the other variables.

In the multivariate analysis (Table 2), patients with cervical spondylosis were more likely to have objective BPPV (odds ratio [OR] = 3.94; 95% CI: 1.28–13.64; p = 0.021) and so were those receiving antihypertensives (OR = 3.02; 95% CI = 1.14–8.41; p = 0.028). Patients on benzodiazepines, by contrast, were more likely to present subjective BPPV (OR, 0.24; 0.06–0.77; p = 0.023).

Discussion

A high proportion of the primary care patients in our series (59.7%) had subjective BPPV. Cervical spondylosis (OR = 3.94) and antihypertensive therapy (OR = 3.02) were significantly associated with objective BPPV, while treatment with benzodiazepines was significantly associated with subjective BPPV (OR = 0.24).
The DHT is considered the gold standard for diagnosing posterior canal BPPV, but the reliability of the diagnosis is strengthened when both vertigo and nystagmus are observed.\textsuperscript{11,15} In a study by Balatsouras,\textsuperscript{6} 63 patients had an initial diagnosis of subjective BPPV based on physical examination findings. However, additional testing with videonystagmography on the morning after recruitment showed that 21 of these patients actually had mild nystagmus that was not visible to the naked eye. Accordingly, 33\% of these patients were re-diagnosed with objective BPPV. An additional 11 patients were diagnosed with another condition and seven were left undiagnosed. Repositioning maneuvers were almost five times more effective in patients initially diagnosed with objective BPPV and were equally effective in patients with objective and subjective BPPV following the regrouping according to the results of the videonystagmography tests. Subjective BPPV therefore is a less reliable diagnosis than objective BPPV, particularly when based on the results of the DHT only (i.e., without additional tests such as videonystagmography).\textsuperscript{3}

The multivariate analysis in our study showed an association between objective BPPV and cervical spondylosis. This link between BPPV and cervical spondylosis has been widely debated. While some authors question whether arthritis of the neck can cause BPPV,\textsuperscript{16} others claim that it can as it would reduce blood flow in this area,\textsuperscript{17} resulting in altered oculovestibular reflexes (on which nystagmus depends) and possibly vertigo.\textsuperscript{18}

The results of our study also show that patients with objective BPPV are three times more likely than those with subjective BPPV to be on antihypertensive therapy. The association between BPPV and hypertension has been reported elsewhere and was first highlighted by Brevern et al.\textsuperscript{19} Other studies have shown that hypertension can increase BPPV recurrence\textsuperscript{20} and time to diagnosis.\textsuperscript{21} In our series, BPPV was associated with hypertension in the bivariate analysis and antihypertensive therapy in the multivariate analysis. Hypertensive patients under pharmacological treatment are probably more representative of the hypertensive population in general. In our series, treatment with benzodiazepines was significantly associated with subjective BPPV. In a prospective case-control study published in October 2018, no association was found between the use of anti-vertigo drugs (betahistine and sulpiride) and the presence or absence of nystagmus.\textsuperscript{22} Our findings, by contrast, are consistent with those of Tan et al.,\textsuperscript{23} who found higher rates of vestibular suppressant medication use in patients who tested positive for vertigo on positional testing than in those who tested positive for both vertigo and nystagmus. When the patients were retested following withdrawal of medication (mostly benzodiazepines and antihistamines), 50\% showed nystagmus (i.e., they had typical BPPV). As current guidelines do not recommend pharmacologic treatment of BPPV,\textsuperscript{24} anti-vertigo medication can be withdrawn in patients with an equivocal diagnosis and tests repeated within approximately a week.

**Limitations**

The original study on which the results of this study are based was designed to evaluate the effectiveness of the Epley maneuver in primary care, not to compare factors associated with the presence or absence of baseline
Table 1  Patient characteristics for the total group and by subgroups of patients with subjective BPPV (vertigo only) and objective BPPV (vertigo and nystagmus) in the Dix-Hallpike text.

|                                           | n     | Total         | Subjective BPPV (n = 80) | Objective BPPV (n = 54) | p value |
|-------------------------------------------|-------|---------------|--------------------------|-------------------------|---------|
| **Median age (IQR), y**                   | 134   | 52.0 (38.2, 68.0) | 49.0 (37.0, 65.2)        | 56.0 (39.0, 70.0)        | 0.160   |
| **Age, n (%)**                            |       |               |                          |                         |         |
| 18–40 y                                   | 134   | 38 (28.4%)    | 23 (28.7%)               | 15 (27.8%)              | 0.203   |
| 41–60 y                                   |       | 43 (32.1%)    | 28 (35.0%)               | 15 (27.8%)              |         |
| 61–80 y                                   |       | 50 (37.3%)    | 29 (36.2%)               | 21 (38.9%)              |         |
| 81–96 y                                   |       | 3 (2.2%)      | 0 (0.0%)                 | 3 (5.6%)                |         |
| **Women, n (%)**                          | 134   | 102 (76.1%)   | 63 (78.8%)               | 39 (72.2%)              | 0.414   |
| **Median time since onset of symptoms (IQR), days** |       |               |                          |                         |         |
| Previous episodes of vertigo, n (%)       | 133   | 63 (47.4%)    | 36 (45.0%)               | 27 (50.9%)              | 0.595   |
| Median severity of vertigo symptoms (Likert scale, 0–10) | 134   | 7.0 [6.0, 8.0] | 7.0 [6.0, 8.0]           | 8.0 [6.2, 8.8]          | 0.250   |
| **Medical history, n (%)**                |       |               |                          |                         |         |
| Viral infection in previous 4 weeks       | 134   | 31 (23.1%)    | 19 (23.8%)               | 12 (22.2%)              | 1.000   |
| Traumatic brain injury                    | 134   | 7 (5.2%)      | 3 (3.8%)                 | 4 (7.4%)                | 0.429   |
| Headache                                  | 134   | 48 (35.8%)    | 25 (31.2%)               | 23 (42.6%)              | 0.202   |
| Anxiety                                   | 130   | 33 (25.4%)    | 19 (24.7%)               | 14 (26.4%)              | 0.840   |
| Depression                                | 130   | 30 (23.1%)    | 16 (20.8%)               | 14 (26.4%)              | 0.527   |
| Hypertension                              | 134   | 34 (25.4%)    | 15 (18.8%)               | 19 (35.2%)              | 0.043   |
| Diabetes mellitus                         | 130   | 19 (14.6%)    | 8 (10.4%)                | 11 (20.8%)              | 0.130   |
| Dyslipidemia                              | 134   | 57 (42.5%)    | 31 (38.8%)               | 26 (48.1%)              | 0.292   |
| Cardiovascular disease                    | 134   | 6 (4.5%)      | 3 (3.8%)                 | 3 (5.6%)                | 0.685   |
| Altered thyroid                           | 134   | 6 (4.5%)      | 4 (5.0%)                 | 2 (3.7%)                | 1.000   |
| Osteoporosis                              | 134   | 16 (11.9%)    | 11 (13.8%)               | 5 (9.3%)                | 0.589   |
| Cervical spondylosis                      | 134   | 22 (16.4%)    | 9 (11.2%)                | 13 (24.1%)              | 0.059   |
| Neck pain                                 | 134   | 64 (47.8%)    | 35 (43.8%)               | 29 (53.7%)              | 0.293   |
| **Pharmacological treatment for BPPV, n (%)** |       |               |                          |                         | 0.468   |
| None                                      |       | 56 (41.8%)    | 37 (46.2%)               | 19 (35.2%)              |         |
| Betaistine as monotherapy                 |       | 69 (51.5%)    | 37 (46.2%)               | 32 (59.3%)              |         |
| Betaistine combination therapy            |       | 2 (1.5%)      | 1 (1.2%)                 | 1 (1.9%)                |         |
| Other anti-vertigo drugs                  |       | 7 (5.2%)      | 5 (6.2%)                 | 2 (3.7%)                |         |
| **Other treatments, n (%)**              |       |               |                          |                         |         |
| Benzodiazepines                           | 134   | 24 (17.9%)    | 16 (20.0%)               | 8 (14.8%)               | 0.498   |
| Antidepressants                           | 134   | 27 (20.1%)    | 13 (16.2%)               | 14 (25.9%)              | 0.192   |
| Antihypertensives                         | 133   | 26 (19.5%)    | 11 (13.8%)               | 15 (28.3%)              | 0.046   |

**Abbreviations**: BPPV: benign paroxysmal positional vertigo; IQR: interquartile range.

Nystagmus in patients with BPPV. Nonetheless, because BPPV is so common in primary care and because there is a dearth of literature on DHT responses in this setting, we believe that this substudy is important as it could help improve the diagnosis of this disease in primary care.

The high prevalence of subjective BPPV observed in our series is logical considering that GPs see more cases of mild BPPV (without nystagmus), have less experience in detecting these cases, and lack the equipment for doing so (e.g., Frenzel goggles and videonystagmography).
whether these cardiovascular factors would worsen BPPV.

Patients with subjective BPPV were more likely to be taking benzodiazepines.

Patients with objective BPPV (vertigo plus nystagmus in the DHT) are more likely to have cervical spondylosis and to be receiving antihypertensive therapy.

Table 2  
Multivariate regression analysis of predictors of nystagmus (without consideration of interactions).

| Independent variable | OR (95% CI) | p value |
|----------------------|-------------|---------|
| Sex                  |             |         |
| Male                 | 0.72 (0.32, 1.61) | 0.430   |
| Female (reference)   | 0.57 (0.23, 1.38) | 0.209   |
| Treatment with benzodiazepines | 0.24 (0.06, 0.77) | 0.023   |
| Treatment with antidepressants | 2.68 (0.94, 8.06) | 0.070   |
| Treatment with antihypertensives | 3.02 (1.14, 8.41) | 0.028   |
| Traumatic brain injury | 3.60 (0.60, 23.95) | 0.159   |
| Osteoporosis          | 0.27 (0.05, 1.03) | 0.072   |
| Cervical spondylosis  | 3.94 (1.28, 13.64) | 0.021   |

Best-fit model according to the Akaike Information Criterion. The initial model included age, sex, time since onset of symptoms, number of previous vertigo episodes, self-rated vertigo severity, recent viral infection, traumatic brain injury, headache, anxiety/depression, hypertension, diabetes mellitus, dyslipidemia, cardiovascular disease, altered thyroid function, osteoporosis, cervical spondylosis, neck pain, pharmacological treatment of vertigo symptoms, and treatment with benzodiazepines, anti-depressants, and antihypertensives.

### Conclusion

BPPV is related in the present study with cervical spondylosis and arterial hypertension. Association of BPPV with cardiovascular risk factors makes recommendable monitoring these patients. Treatment with benzodiazepines can worsen the detection of nystagmus so it is never indicated in these patients. Future research should focus on determining whether interrupt sedatives medication before testing BPPV could improve nystagmus detection, providing more reliable diagnoses and better prognosis for patients.

### Funding

This project received a research grant from the Carlos III Institute of Health, Ministry of Economy and Competitiveness (Spain), awarded on the 2013 call under the Health Strategy Action 2013–2016, within the National Research Program oriented to Societal Challenges, within the Technical, Scientific and Innovation Research National Plan 2013–2016, with reference PI13/01396, co-funded with European Union ERDF funds. It was also funded by the cycle XIV (2013) research grant from the Spanish Primary Care Network (REAP) and a predoctoral grant from the Jordi Gol Institute for Research in Primary Care (IDIAP Jordi Gol) (2014/005E). IDIAP Jordi Gol also funded the translation of this article into English.

### Keypoints

**What is known about the topic**

- Posterior canal benign paroxysmal positional vertigo (BPPV) is the most common type of vertigo seen in primary care settings.
- This condition can be adequately diagnosed and treated with the Dix-Hallpike (DH) test and canal repositioning maneuvers.
- The DHT provokes vertigo in the absence of observable nystagmus in a considerable proportion of cases (11%–48%).

**What this study adds**

- The prevalence of subjective BPPV detected in our primary care setting (59.71%) was higher than that observed in previous studies.
- Patients with subjective BPPV are more likely to be taking benzodiazepines.
- Patients with objective BPPV (vertigo plus nystagmus in the DHT) are more likely to have cervical spondylosis and to be receiving antihypertensive therapy.

### Conflicts of interest

None.

### Acknowledgements

The authors gratefully acknowledge the technical and scientific assistance provided by the Primary Healthcare Research Unit of Costa de Ponent Primary Healthcare University Research Institute IDIAP-Jordi Gol. We also thank Neus Profitós and Celsa Fernández who were responsible for safeguarding the randomization sequence list. Finally, we thank all the participants of the Grupo de Estudio del Vértigo en Atención Primaria Florida: Estrella Rodero Pérez, Xavier Monteverde Curtó, Carles Rubio Ripollés, Noemi Moreno Farrés, Jean Carlos Gómez Nova, Johan José Villarreal Miñano, Diana Lizzeth Pacheco Erazo, Raquel Adroer Martori, Anna Aguilera Margalejo, Olga Lucia Arias Agudelo, Silvia Cañadas Crespo, Laura Illamola Martín, Marta Sarró Maluquer, Lluís Solsona Díaz, Rosa Sorando Alastrauey (Equip d’Atenció Primària Florida Nord, Institut Català de la Salut, Hospital de Llobregat, Barcelona, Spain). Austria Matos Mèndez, Marta Bardina Santos (Equip d’Atenció Primària Florida Sud, Institut Català de la Salut, Hospital de Llobregat, Barcelona, Spain).

Lead author: José Luis Ballvé Moreno.
References

1. Benecke H, Agus S, Kuessner D, Goodall G, Strupp M. The burden and impact of vertigo: Findings from the REVERT patient registry. Front Neurol. 2013;4:1–7.
2. Froehling DA, Bowen JM, Mohr DN, Brey RH, Beatty CW, Wollan PC, et al. The canalith repositioning procedure for the treatment of benign paroxysmal positional vertigo: a randomized controlled trial. Mayo Clin Proc. 2000;75:695–700.
3. Mizukoshi K, Watanabe Y, Shojaku H, Okubo J, Watanabe I. Epidemiological studies on benign paroxysmal positional vertigo in Japan. Acta Otolaryngol Suppl. 1988;447:67–72.
4. Kim JS, Zee DS. Benign paroxysmal positional vertigo. N Engl J Med. 2014;370:1138–47.
5. Balatsouras DG, Korres SG. Subjective benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 2012;146:98–103.
6. Haynes DS, Resser JR, Labadie RF, Girasole CR, Kovach BT, Scheker LE, et al. Treatment of benign positional vertigo using the semont maneuver: efficacy in patients presenting without nystagmus. Laryngoscope. 2002;112:796–801.
7. Alvarenga GA, Barbosa MA, Porto CC. Benign paroxysmal positional vertigo without nystagmus: diagnosis and treatment. Braz J Otorhinolaryngol. 2011;77:799–804.
8. Norrè ME. Reliability of examination data in the diagnosis of benign paroxysmal positional vertigo. Am J Otol. 1995;16:806–10.
9. Weider DJ, Ryder CJ, Stram JR. Benign paroxysmal positional vertigo: analysis of 44 cases treated by the canalith repositioning procedure of Epley. Am J Otol. 1994;15:321–6.
10. Grill E, Penger M, Kentala E. Health care utilization, prognosis and outcomes of vestibular disease in primary care settings: systematic review. J Neurol. 2016;263:36–44.
11. Ballvé JL, Carrillo-Muñoz R, Rando-Matos Y, Villar I, Cunillera O, Almeda J, et al. Effectiveness of the Epley maneuver in posterior canal benign paroxysmal positional vertigo: a randomised clinical trial in primary care. Br J Gen Pract. 2019;69:e52–60.
12. Bhattacharyya N, Gubbiels SP, Schwartz SR, Edlow JA, El-Kashlan H, Fife T, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update) executive summary. Otolaryngol Head Neck Surg. 2017;156:403–16.
13. Ballvé Moreno JL, Carrillo Muñoz R, Villar Balboa I, Rando Matos Y, Arias Agudelo OR, Vasudeva A, et al. Effectiveness of the Epley’s maneuver performed in primary care to treat posterior canal benign paroxysmal positional vertigo: study protocol for a randomized controlled trial. Trials. 2014;15:179.
14. Dieterich M, Obermann M, Celebisoy N. Vestibular migraine: the most frequent entity of episodic vertigo. J Neurol. 2016;263 Suppl. 1:S82–9.
15. Kerber KA. Benign paroxysmal positional vertigo: opportunities squandered. Ann N Y Acad Sci. 2015;1343:106–12.
16. Brandt T, Bronstein AM. Cervical vertigo. J Neurol Neurosurg Psychiatry. 2001;71:8–12.
17. Li Y, Peng B. Pathogenesis diagnosis and treatment of cervical vertigo. Pain Phys. 2014;18:E583–95.
18. Peng B. Cervical vertigo: historical reviews and advances. World Neurosurg. 2018;109:347–50.
19. von Bremen M, Radtke A, Lezius F, Feldmann M, Ziese T, Lempert T, et al. Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry. 2007;78:710–5.
20. De Stefano A, Dispenza F, Suarez H, Perez-Fernandez N, Manrique-Huarte R, Ban JH, et al. A multicenter observational study on the role of comorbidities in the recurrent episodes of benign paroxysmal positional vertigo. Auris Nasus Larynx. 2014;41:31–6.
21. Brandt T, Huppert D, Hecht J, Karch C, Strupp M. Benign paroxysmal positional vertigo: a long-term follow-up (6–17 years) of 125 patients. Acta Otolaryngol. 2006;126:160–3.
22. González-Aguado R, Doménech-Vadillo E, Álvarez-Morujó de Sande MG, Guerra-Jiménez G, Domínguez-Durán E. Subjec- tive benign paroxysmal positional vertigo in patients with osteoporosis or migraine. Braz J Otorhinolaryngol. 2018, pii:S1808-8694(18)30293-3.
23. Tan J, Yu D, Feng Y, Song Q, You J, Shi H, et al. First-referral presentations of patients with benign paroxysmal positional vertigo who were negative on positional testing and who lacked nystagmus. Eur Arch Otorhinolaryngol. 2015;272:3247–51.
24. Fife TD, Iverson DJ, Lempert T, Furman JM, Baloh RW, Tusa RJ, et al. Quality Standards Subcommittee American Academy of Neurology. Practice parameter: therapies for benign paroxysmal positional vertigo (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2008;70:2067–74.